查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1403513

甲溝炎治療市場至2030年的預測：按產品、類型、最終用戶和地區分類的全球分析

Paronychia Treatment Market Forecasts to 2030 - Global Analysis By Product, Type, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的資料，2023年全球甲溝炎治療市場規模為 5.0734 億美元，預計在預測期內年複合成長率為 9.2%，到2030年將達到 9.3942 億美元。

甲溝炎是一種常見的指甲感染疾病，其特徵是指甲和腳趾甲周圍的皮膚發炎。它是由細菌、真菌或兩者兼而有之引起的，會導致發紅、腫脹和疼痛。治療需要溫水浴，適當的傷口引流，針對細菌感染的局部或口服抗生素以及針對真菌感染的口服抗真菌藥物，並且在嚴重或復發的情況下可能需要手術治療。

糖尿病患者增加

由於免疫系統減弱、神經損傷和血液循環減少，糖尿病患者更容易受到甲真菌病等指甲感染疾病，使他們更容易受到細菌和真菌指甲感染疾病。隨著全球糖尿病盛行率的增加，糖尿病相關併發症（包括指甲疾病）的發生率也增加。糖尿病患者在控制感染疾病常常面臨挑戰，需要及時有效地治療甲溝炎。

假藥

仿冒和不受監管的藥物是一個嚴重的威脅，可能會給尋求甲溝炎治療方法的人無效、不合格或有害的治療方法。這些核准的藥物缺乏品管以及適當的功效和安全標準，引起了醫療保健專業人員和患者對其治療的可靠性和潛在副作用的擔憂。這些非正品產品的存在破壞了人們對市場提供的藥品的信任並阻礙了市場的成長。

技術進步

創新技術可以改進配方、標靶化給藥並增強診斷工具。奈米技術、經皮吸收貼片以及先進的影像檢查和分子測試使治療方法更加有效和精確。此外，遠端醫療有助於遠距諮詢並擴大獲得專業護理的機會。這些技術進步改善治療效果、患者體驗和甲溝炎治療的整體前景，推動市場創新和成長機會。

認知有限

缺乏對甲溝炎、其症狀以及及時接受醫療照護重要性的了解，可能會導致診斷和治療的延遲。對預防措施和可用治療方案認知不足可能會妨礙早期療育並導致指甲感染疾病的進展。這種有限的認知會減少患者數量並阻礙有效甲溝炎治療方法的採用，影響市場成長。

COVID-19 的影響

致命的冠狀病毒迅速在世界各地傳播，使醫院不堪重負，佔用了資源，並限制了獲得非必要衛生服務的機會。這對醫療保健系統造成了重大干擾，不僅影響甲溝炎的診斷、治療和管理，而且還延遲和減少了獲得醫療保健服務的機會。遭受感染疾病和疼痛和發炎等不良影響的人們必須等待服務恢復才能解決他們的問題。

慢性甲溝炎區隔預計將成為預測期內最大的區隔

據估計，慢性甲溝炎所佔比例最大。慢性甲溝炎是一種長期疾病，通常由真菌或細菌感染、刺激物或誘發因素（例如重複性創傷或潛在疾病）引起。慢性甲溝炎的治療包括局部抗真菌藥物和抗生素、口服療法、溫水浴以及解決潛在刺激的預防措施。慢性甲溝炎也會反覆復發，需要長期的專門治療。因此，存在專門用於治療此類疾病的市場。

慶大霉素軟膏預計在預測期內年複合成長率最高

預計慶大霉素軟膏細分市場在預測期內將出現良好的成長。慶大霉素軟膏含有慶大霉素，這是一種對多種細菌有效的抗生素。當直接塗布在指甲的受影響區域時，慶大霉素軟膏可以針對細菌感染，減少發炎並促進癒合。其局部塗布和抗菌特性使其成為輕度至中度細菌性甲溝炎的有價值的治療選擇。該領域專門針對需要標靶抗菌治療的患者，並為對抗甲溝炎等細菌性指甲感染疾病的局部治療市場做出了貢獻。

佔有率最大的地區

由於醫療保健意識的提高，指甲感染疾病的上升以及醫療保健基礎設施的改善，亞太地區在估計期間佔據了最大的市場佔有率。該地區多樣化的人口和生活方式的變化導致甲溝炎發病率增加。此外，患有甲溝炎的人數增加，治療該問題的支出也增加，改善衛生基礎設施和提高對指甲感染認識的有利政府措施的迅速普及，推動市場成長的需求。

年複合成長率最高的地區：

由於老年人口的迅速增加，人們對可行治療方法的了解不斷增加以及美國和加拿大等國家主要市場參與者的強大影響力，預計北美地區將在預測期內實現盈利成長。此外，尖端甲溝炎治療方法（例如新的局部療法、抗真菌藥物和抗生素）的快速開拓可能會增加診所和醫院提供的治療方法種類，並對市場產生積極影響。

免費客製化服務：

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多3家公司）
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶興趣對主要國家的市場估計、預測和年複合成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章 執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 調查來源
    • 主要調查來源
    • 二次調查來源
    • 先決條件

第3章 市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章 全球甲溝炎治療市場：依產品

  • 莫匹羅星軟膏
  • 慶大霉素軟膏
  • 夫西地酸軟膏
  • 雙氯西林
  • 其他產品

第6章 全球甲溝炎治療市場：依類型

  • 慢性甲溝炎
  • 急性甲溝炎
  • 化膿性甲溝炎
  • 念珠菌性甲溝炎
  • 其他類型

第7章 全球甲溝炎治療市場：依最終用戶分類

  • 皮膚科中心
  • 醫院和診所
  • 其他最終用戶

第8章 全球甲溝炎治療市場：依地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • Glenmark Generics Ltd
  • Eli Lilly Company
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd
  • Jonakayem Pharma Formulation
  • Fougera Pharmaceuticals Inc
  • Allergen Plc
  • Johnson & Johnson Services Inc.
  • Bayer AG
  • Merck & Co. Inc.
  • Perrigo New York Inc.
  • Novartis AG
  • Pfizer Inc.
  • Taro Pharmaceutical Industries
  • Sandoz International GmbH
Product Code: SMRC24738

According to Stratistics MRC, the Global Paronychia Treatment Market is accounted for $507.34 million in 2023 and is expected to reach $939.42 million by 2030 growing at a CAGR of 9.2% during the forecast period. Paronychia is a common nail infection characterized by inflammation of the skin surrounding the fingernail or toenail. This is caused by bacteria, fungi, or both, leading to redness, swelling, and pain. Treatment involves warm soaks, proper wound drainage, topical or oral antibiotics for bacterial infections, antifungal medications for fungal cases, and in severe or recurrent instances, surgical intervention may be necessary.

Market Dynamics:

Driver:

Significant rise in diabetes patients

Diabetic individuals are more susceptible to nail infections like paronychia due to compromised immune systems, nerve damage, and reduced blood circulation, making them susceptible to bacterial or fungal nail infections. With the escalating, global diabetes prevalence, there's been a corresponding increase in the incidence of diabetic-related complications, including nail disorders. Diabetic patients often experience challenges in managing infections, necessitating prompt and effective treatment for paronychia.

Restraint:

Counterfeit medications

Counterfeit or unregulated medications pose a serious threat, potentially offering ineffective, substandard, or even harmful treatments to individuals seeking remedies for paronychia. Such unauthorized drugs lack quality control, proper efficacy, and safety standards, raising concerns among healthcare professionals and patients about treatment reliability and potential adverse effects. The presence of these illegitimate products undermines trust in the market's offerings, hindering the market's growth.

Opportunity:

Advancements in technology

Innovative technologies offer improved drug formulations, targeted delivery systems, and enhanced diagnostic tools. Nanotechnology, transdermal patches, and sophisticated imaging or molecular testing enable more effective and precise treatment approaches. Additionally, telemedicine facilitates remote consultations, expanding access to specialized care. These technological advancements enhance treatment efficacy, patient experience, and the overall landscape of paronychia treatments, fostering opportunities for innovation and growth within the market.

Threat:

Limited awareness

Insufficient knowledge among individuals about paronychia, its symptoms, and the importance of seeking timely medical care may result in delayed diagnosis and treatment. Lack of awareness about preventive measures and available treatment options could hinder early intervention, leading to the progression of nail infections. This limited awareness impacts market growth by reducing the patient pool and impeding the adoption of effective paronychia treatments.

COVID-19 Impact

The deadly corona virus spread quickly around the world, overwhelming hospitals, redirecting resources, and restricting access to non-essential medical services. This caused major disruptions in healthcare systems that impacted paronychia diagnosis, treatment, and management, as well as delayed or decreased access to healthcare services. In order to get their problems resolved those who are experiencing infections and adverse consequences, including pain and inflammation, must wait for the services to resume.

The chronic paronychia segment is expected to be the largest during the forecast period

The chronic paronychia segment is estimated to hold the largest share. Chronic paronychia is a long-term condition that often arises from fungal or bacterial infections, irritants, or predisposing factors such as repetitive trauma or underlying health conditions. Treatments for chronic paronychia include topical antifungal or antibiotic medications, oral therapies, warm soaks, and preventive measures addressing potential irritants. Moreover, chronic paronychia requires long-term, specialised therapy due to its recurrent nature. As a result, there is a dedicated market focus on treating this type of illness.

The gentamicin ointment segment is expected to have the highest CAGR during the forecast period

The gentamicin ointment segment is anticipated to have lucrative growth during the forecast period. Gentamicin ointment contains gentamicin, an antibiotic effective against a wide range of bacteria. Applied directly to the affected nail area, gentamicin ointment targets bacterial infections, reducing inflammation and promoting healing. Furthermore, its localised application and antibacterial properties make it a valuable treatment option for mild-to-moderate bacterial paronychia cases. This segment caters specifically to individuals requiring targeted antimicrobial therapy, contributing to the market's array of topical treatments for addressing bacterial nail infections like paronychia.

Region with largest share:

Asia Pacific commanded the largest market share during the extrapolated period due to increasing healthcare awareness, a rising prevalence of nail infections, and improving healthcare infrastructure. The region's diverse population and changing lifestyles contribute to the growing incidence of paronychia. Moreover, due to the increased population base suffering from paronychia and their rising spending on the treatment of this issue, and the surging prevalence of favourable government initiatives aimed at improving healthcare infrastructure and promoting awareness about nail infections, this is driving the demand for market growth.

Region with highest CAGR:

North America is expected to witness profitable growth over the projection period due to a surge in the geriatric population, growing people's knowledge of viable treatments, and the robust presence of major market players in countries like the US and Canada. Moreover, the quick development of cutting-edge paronychia treatment alternatives, such as new topical therapies, antifungal medications, and antibiotics, which have increased the variety of treatment methods offered in clinics and hospitals, is likely to impact the market positively.

Key players in the market:

Some of the key players in the Paronychia Treatment Market include Glenmark Generics Ltd, Eli Lilly Company, GlaxoSmithKline plc, Teva Pharmaceutical Industries Ltd, Jonakayem Pharma Formulation, Fougera Pharmaceuticals Inc, Allergen Plc, Johnson & Johnson Services Inc., Bayer AG, Merck & Co. Inc., Perrigo New York Inc., Novartis AG, Pfizer Inc., Taro Pharmaceutical Industries and Sandoz International GmbH.

Key Developments:

In January 2023, The National Medical Products Administration of China announced that they have approved the mobocertinib for treatment of the adult patients with advanced and metastatic non-small lung cancer. The newly developed treatment technique was mostly experienced with mobocertinib including paronychia, diarrhoea, rash, and decreased appetite.

Products Covered:

  • Mupirocin Ointment
  • Gentamicin Ointment
  • Fusidic Acid Ointment
  • Dicloxacillin
  • Other Products

Types Covered:

  • Chronic Paronychia
  • Acute Paronychia
  • Pyogenic Paronychia
  • Candidal Paronychia
  • Other Types

End Users Covered:

  • Dermatology Centers
  • Hospitals & Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 End User Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Paronychia Treatment Market, By Product

  • 5.1 Introduction
  • 5.2 Mupirocin Ointment
  • 5.3 Gentamicin Ointment
  • 5.4 Fusidic Acid Ointment
  • 5.5 Dicloxacillin
  • 5.6 Other Products

6 Global Paronychia Treatment Market, By Type

  • 6.1 Introduction
  • 6.2 Chronic Paronychia
  • 6.3 Acute Paronychia
  • 6.4 Pyogenic Paronychia
  • 6.5 Candidal Paronychia
  • 6.6 Other Types

7 Global Paronychia Treatment Market, By End User

  • 7.1 Introduction
  • 7.2 Dermatology Centers
  • 7.3 Hospitals & Clinics
  • 7.4 Other End Users

8 Global Paronychia Treatment Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 Glenmark Generics Ltd
  • 10.2 Eli Lilly Company
  • 10.3 GlaxoSmithKline plc
  • 10.4 Teva Pharmaceutical Industries Ltd
  • 10.5 Jonakayem Pharma Formulation
  • 10.6 Fougera Pharmaceuticals Inc
  • 10.7 Allergen Plc
  • 10.8 Johnson & Johnson Services Inc.
  • 10.9 Bayer AG
  • 10.10 Merck & Co. Inc.
  • 10.11 Perrigo New York Inc.
  • 10.12 Novartis AG
  • 10.13 Pfizer Inc.
  • 10.14 Taro Pharmaceutical Industries
  • 10.15 Sandoz International GmbH

List of Tables

  • Table 1 Global Paronychia Treatment Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 4 Global Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 5 Global Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 6 Global Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 7 Global Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 8 Global Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 9 Global Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 10 Global Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 11 Global Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 12 Global Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 13 Global Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 14 Global Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 15 Global Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 16 Global Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 17 Global Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 18 North America Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 19 North America Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 20 North America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 21 North America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 22 North America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 23 North America Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 24 North America Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 25 North America Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 26 North America Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 27 North America Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 28 North America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 29 North America Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 30 North America Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 31 North America Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 32 North America Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 33 North America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 34 North America Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 35 Europe Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 36 Europe Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 37 Europe Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 38 Europe Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 39 Europe Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 40 Europe Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 41 Europe Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 42 Europe Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 43 Europe Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 44 Europe Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 45 Europe Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 46 Europe Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 47 Europe Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 48 Europe Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 49 Europe Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 50 Europe Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 51 Europe Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 52 Asia Pacific Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 53 Asia Pacific Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 54 Asia Pacific Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 55 Asia Pacific Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 56 Asia Pacific Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 57 Asia Pacific Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 58 Asia Pacific Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 59 Asia Pacific Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 60 Asia Pacific Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 61 Asia Pacific Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 62 Asia Pacific Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 63 Asia Pacific Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 64 Asia Pacific Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 65 Asia Pacific Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 66 Asia Pacific Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 67 Asia Pacific Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 68 Asia Pacific Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 69 South America Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 70 South America Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 71 South America Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 72 South America Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 73 South America Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 74 South America Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 75 South America Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 76 South America Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 77 South America Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 78 South America Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 79 South America Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 80 South America Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 81 South America Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 82 South America Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 83 South America Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 84 South America Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 85 South America Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)
  • Table 86 Middle East & Africa Paronychia Treatment Market Outlook, By Country (2021-2030) ($MN)
  • Table 87 Middle East & Africa Paronychia Treatment Market Outlook, By Product (2021-2030) ($MN)
  • Table 88 Middle East & Africa Paronychia Treatment Market Outlook, By Mupirocin Ointment (2021-2030) ($MN)
  • Table 89 Middle East & Africa Paronychia Treatment Market Outlook, By Gentamicin Ointment (2021-2030) ($MN)
  • Table 90 Middle East & Africa Paronychia Treatment Market Outlook, By Fusidic Acid Ointment (2021-2030) ($MN)
  • Table 91 Middle East & Africa Paronychia Treatment Market Outlook, By Dicloxacillin (2021-2030) ($MN)
  • Table 92 Middle East & Africa Paronychia Treatment Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 93 Middle East & Africa Paronychia Treatment Market Outlook, By Type (2021-2030) ($MN)
  • Table 94 Middle East & Africa Paronychia Treatment Market Outlook, By Chronic Paronychia (2021-2030) ($MN)
  • Table 95 Middle East & Africa Paronychia Treatment Market Outlook, By Acute Paronychia (2021-2030) ($MN)
  • Table 96 Middle East & Africa Paronychia Treatment Market Outlook, By Pyogenic Paronychia (2021-2030) ($MN)
  • Table 97 Middle East & Africa Paronychia Treatment Market Outlook, By Candidal Paronychia (2021-2030) ($MN)
  • Table 98 Middle East & Africa Paronychia Treatment Market Outlook, By Other Types (2021-2030) ($MN)
  • Table 99 Middle East & Africa Paronychia Treatment Market Outlook, By End User (2021-2030) ($MN)
  • Table 100 Middle East & Africa Paronychia Treatment Market Outlook, By Dermatology Centers (2021-2030) ($MN)
  • Table 101 Middle East & Africa Paronychia Treatment Market Outlook, By Hospitals & Clinics (2021-2030) ($MN)
  • Table 102 Middle East & Africa Paronychia Treatment Market Outlook, By Other End Users (2021-2030) ($MN)